Landiolol

As a representative short-acting highly selective β1-receptor blocker, landiolol specifically blocks cardiac β1-adrenergic receptors to slow down heart rate and reduce myocardial oxygen consumption, while having minimal effect on β2 receptors in bronchial and vascular smooth muscles. It also has the pharmacokinetic advantages of rapid onset, short half-life and quick disappearance of effect after drug withdrawal. Clinically, it is mainly used for the emergency treatment of tachyarrhythmias during surgery (including atrial fibrillation, atrial flutter and sinus tachycardia), and can also be used for the prevention of perioperative myocardial ischemia. It is particularly suitable for patients with comorbid airway hyperresponsiveness and chronic obstructive pulmonary disease, avoiding the risk of adverse reactions of traditional non-selective β-receptor blockers.

At present, the global market size of landiolol exceeds 320 million US dollars, with a compound annual growth rate maintained at around 7.8%. The growth momentum mainly comes from the increasing demand for perioperative arrhythmia management and the expansion of emergency indications. China is the regional market with the fastest growth rate of landiolol, with a compound annual growth rate of 12.3%. The competitive landscape shows a coexistence of original research drugs and generics. So far, 7 domestic enterprises have obtained approval for generic drug preparations. After the centralized procurement, the terminal price has dropped by about 62%, and the accessibility for patients has been greatly improved, driving the continuous increase in the demand for active pharmaceutical ingredients.

The original research enterprise of landiolol is Ono Pharmaceutical Co., Ltd. of Japan, with the original brand name "Onoact". The expiration date of its core compound patent in Japan is 2007, and the compound patent in China has expired. The main dosage form approved for the original research product is injection, with specifications of 50mg and 125mg, which has been included in the *Catalogue of Reference Preparations for Chemical Drugs* issued by the NMPA. In China, there are currently 11 registration numbers for landiolol active pharmaceutical ingredients, 8 of which are in status A (can be used in marketed preparations), and another 15 domestic landiolol injection varieties have been approved for marketing.(Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of landiolol impurity reference standards, covering the entire research chain including process impurities and degradation impurities. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can fully meet the needs of various scenarios such as quality research and registration declaration of active pharmaceutical ingredient and preparation enterprises.

CATO/佳途科技提供兰地洛尔全套杂质标准品，覆盖工艺杂质、降解杂质等全研究链条，大部分产品现货供应，现货产品16:00前下单当天发货，所有标准品均符合中国药典、FDA等多法规合规要求，可充分满足原料药及制剂企业的质量研究、注册申报等各类场景需求。